AFT Pharmaceuticals Distribution Notice

Section 1: Issuer information				
Name of issuer	AFT Pharmaceuticals Limited			
Financial product name/description	AFT Pharmaceuticals Limited Ordinary Shares			
NZX ticker code	AFT			
ISIN (If unknown, check on NZX website)	NZAFTE0001S4			
Type of distribution (Please mark with an X in the relevant box/es)	Full Year		Quarterly	
	Half Year	X	Special	
	DRP applies			
Record date	03 December 2026			
Ex-Date (one business day before the Record Date)	02 December 2026			
Payment date (and allotment date for DRP)	17 December 2026			
Total monies associated with the distribution	$1,048,747.60 (104,874,660 shares @$0.01000000/share)			
Source of distribution (for example, retained earnings)	Retained earnings			
Currency	New Zealand Dollars			
Section 2: Distribution amounts per financial product				
Gross distribution	$ 0.01388889			
Gross taxable amount	$ 0.01388889			
Total cash distribution	$0.01000000			
Excluded amount (applicable to listed PIEs)	N/A			
Supplementary distribution amount	$0.00176471			
Section 3: Imputation credits and Resident Withholding Tax				
Is the distribution imputed	Fully imputed			
	~~Partial imputation~~			
	~~No imputation~~			
If fully or partially imputed, please state imputation rate as % applied	28%			
Imputation tax credits per financial product	$0.00388889			
Resident Withholding Tax per financial product	$0.00069444			

Section 4: Distribution re-investment plan (if applicable)		
DRP % discount (if any)	N/A	
Start date and end date for determining market price for DRP	N/A	N/A
Date strike price to be announced (if not available at this time)	N/A	
Specify source of financial products to be issued under DRP programme (new issue or to be bought on market)	N/A	
DRP strike price per financial product	N/A	
Last date to submit a participation notice for this distribution in accordance with DRP participation terms	N/A	
Section 5: Authority for this announcement		
Name of person authorised to make this announcement	Stuart Houliston	
Contact person for this announcement	Stuart Houliston	
Contact phone number	+64 9 488 0232	
Contact email address	stuart.houliston@aftpharm.com	
Date of release through MAP	26 November 2026	